The choice of first-line chronic myelogenous leukemia treatment.
about
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaTyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functionsMPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.Isolated Ocular Manifestation of Relapsed Chronic Myelogenous Leukemia Presenting as Myeloid Blast Crisis in a Patient on Imatinib Therapy: A Case Report and Review of the Literature.Imatinib mesylate in chronic myeloid leukemia: frontline treatment and long-term outcomes.Toxicity of the mixture of selected antineoplastic drugs against aquatic primary producers.Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting.Impact of Imatinib on the Fertility of Male Patients with Chronic Myelogenous Leukaemia in the Chronic Phase.19F-NMR-Based Dual-Site Reporter Assay for the Discovery and Distinction of Catalytic and Allosteric Kinase Inhibitors.
P2860
Q26781539-70683459-87DC-4F52-B7A0-17871B94D7FAQ28078946-7BF1C3F3-077A-4B38-8141-7DA1F164EFA3Q35905629-F8754DBD-045B-4251-848D-7F081B62BEEDQ38714657-F37C498D-8E56-4741-BD05-C8CD588A8CABQ38725366-B334902A-FDCC-4CA5-B371-CD7AC8C3F2D7Q40119818-A0BB09C0-E7C1-408C-8129-EBA832F5FF76Q48253155-B4CB65DD-6E0C-4896-B112-3D80B322A595Q53119368-88877A5A-D63F-44D4-82E9-F228F526C111Q54979398-0BAA7F26-A1FA-4234-B115-C73422765339
P2860
The choice of first-line chronic myelogenous leukemia treatment.
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The choice of first-line chronic myelogenous leukemia treatment.
@ast
The choice of first-line chronic myelogenous leukemia treatment.
@en
type
label
The choice of first-line chronic myelogenous leukemia treatment.
@ast
The choice of first-line chronic myelogenous leukemia treatment.
@en
prefLabel
The choice of first-line chronic myelogenous leukemia treatment.
@ast
The choice of first-line chronic myelogenous leukemia treatment.
@en
P2860
P921
P1433
P1476
The choice of first-line chronic myelogenous leukemia treatment.
@en
P2093
Giovanna Rege-Cambrin
P2860
P304
P356
10.1007/S00277-015-2321-3
P478
94 Suppl 2
P577
2015-03-27T00:00:00Z
2015-04-01T00:00:00Z